TAO Synergies Inc. operates as a biopharmaceutical company. The company is primarily focused on developing a product platform based upon Bryostatin-1, for the treatment of Alzheimer's disease (AD), which is in the clinical testing stage. It is also evaluating potential therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis (MS), and Niemann-Pick Type C disease, which have undergone pre-clinical testing. TAO Synergies Inc. was formerly known as Synaptogenix, Inc. and changed its name to TAO Synergies Inc. in June 2025. The company was incorporated in 2012 and is headquartered in New York, New York.n as Synaptogenix, Inc. and changed its name to TAO Synergies Inc. in June 2025. The company was incorporated in 2012 and is headquartered in New York, New York. Show more

Location: 1185 Avenue of the Americas, New York, NY, 10036, United States | Website: https://www.synaptogen.com | Industry: Biotechnology | Sector: Healthcare